


## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### LISTING OF CLAIMS:


1. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and, as active ingredient,
- an acryloyl distamycin derivative of formula (I):



wherein:

R<sub>1</sub> is a bromine or chlorine atom;

R<sub>2</sub> is a distamycin or distamycin-like framework; is a group of formula (II)



wherein


m is an integer from 0 to 2;

n is an integer from 2 to 5;

r is 0 or 1;

X and Y are, the same or different and independently for each heterocyclic ring, a nitrogen atom or a CH group;


G is phenylene, a 5 or 6 membered saturated or unsaturated heterocyclic ring with from 1 to 3 heteroatoms selected among N, O or S, or it is a group of formula (III) below:



wherein O is a nitrogen atom or a CH group and W is an oxygen or sulfur atom or it is a group NR<sub>3</sub>

wherein  $R_3$  is hydrogen or  $C_1$ - $C_4$  alkyl;

$B$  is selected from the group consisting of



wherein  $R_4$  is cyano, amino, hydroxy or  $C_1$ - $C_4$  alkoxy;  $R_5$ ,  $R_6$  and  $R_7$ , the same or different, are

hydrogen or  $C_1$ - $C_4$  alkyl; or a pharmaceutically acceptable salt thereof; and


a protein kinase inhibitor[.]; wherein said pharmaceutical composition has a synergistic antineoplastic effect.

2. (Original) A pharmaceutical composition according to claim 1 wherein the protein kinase inhibitor is selected from the group consisting of STI571, ZD-1839, OSI-774, PKI 166, EKB-569, GW572016, CEP 2563, UCN-01, GCP 41251 (STI 412), Safingol, Perifosine, SU 5416, CGP 79787, CP-564959, ZD 6474, ZD 2171, SU-11248, Flavopiridol, and CI-202.

3. (Original) A pharmaceutical composition according to claim 2 wherein the protein kinase inhibitor is selected from the group consisting of STI571, ZD-1839, OSI-774 and SU 5416.


4. (Cancelled)

5. (Currently Amended) A pharmaceutical composition according to claim [[4]] 1 comprising an acryloyl distamycin derivative of formula (I) wherein  $R_1$  and  $R_2$  are as defined in claim [[4]] 1,  $r$  is 0,  $m$  is 0 or 1,  $n$  is 4,  $X$  and  $Y$  are both  $\text{CH}$  groups and  $B$  is selected from:



wherein R<sub>4</sub> is cyano or hydroxy and R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub>, the same or different, are hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl.

6. (Original) A pharmaceutical composition according to claim 5 comprising an acryloyl distamycin derivative of formula (I) wherein R<sub>1</sub> is bromine, R<sub>2</sub> is a group of formula (II) wherein r and m are 0, n is 4, X and Y are CH, B is a group of formula




wherein R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are hydrogen atoms, optionally in the form of a pharmaceutically acceptable salt.

7. (Original) A pharmaceutical composition according to claim 1 comprising an acryloyl distamycin derivative, optionally in the form of a pharmaceutically acceptable salt, selected from the group consisting of:

1. N-(5-{[(5-{[(5-{[(2-{[amino(imino)methyl]amino}ethyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
2. N-(5-{[(5-{[(5-{[(2-{[amino(imino)methyl]amino}propyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
3. N-(5-{[(5-{[(5-{[(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
4. N-(5-{[(5-{[(5-{[(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-imidazole-2-carboxamide hydrochloride;
5. N-(5-{[(5-{[(5-{[(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-3-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrazole-5-carboxamide hydrochloride;

6. N-(5-{[(5-{[(5-{[(3-amino-3-oxopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-3-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrazole-5-carboxamide;
  7. N-(5-{[(5-{[(5-{[(2-{[amino(imino)methyl]amino}ethyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-chloroacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
  8. N-(5-{[(5-{[(5-{[amino(imino)methyl]amino}propyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
  9. N-(5-{[(5-{[(5-{[(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride; and
  10. N-{5-[(5-[(5-[(5-[(3-[(aminocarbonyl)amino]propyl)amino)carbonyl]-1-methyl-1H-pyrrol-3-yl)amino)carbonyl]-1-methyl-1H-pyrrol-3-yl)amino)carbonyl]-1-methyl-1H-pyrrol-3-yl}-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.
8. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and, as active ingredient,
- N-(5-{[(5-{[(5-{[(2-{[amino(imino)methyl]amino}ethyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride (Brostallicin); and
  - a protein kinase inhibitor selected from the group consisting of STI571, ZD-1839, OSI-774, and SU 5416.


9. (Currently Amended) Product[[s]] comprising an acryloyl distamycin derivative of formula (I):



wherein:

R<sub>1</sub> is a bromine or chlorine atom;

R<sub>2</sub> is a ~~distamycin or distamycin-like framework~~; is a group of formula (II)



wherein


m is an integer from 0 to 2;

n is an integer from 2 to 5;

r is 0 or 1;

X and Y are, the same or different and independently for each heterocyclic ring, a nitrogen atom or a CH group;


G is phenylene, a 5 or 6 membered saturated or unsaturated heterocyclic ring with from 1 to 3 heteroatoms selected among N, O or S, or it is a group of formula (III) below:



wherein Q is a nitrogen atom or a CH group and W is an oxygen or sulfur atom or it is a group NR<sub>3</sub>

wherein R<sub>3</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

B is selected from the group consisting of



wherein R<sub>4</sub> is cyano, amino, hydroxy or C<sub>1</sub>-C<sub>4</sub> alkoxy; R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub>, the same or different, are


hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; or a pharmaceutically acceptable salt thereof; and a protein kinase inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of tumors.

10. (Currently Amended) Product[[s]] according to claim 9 wherein the protein kinase inhibitor is selected from the group consisting of STI571, ZD-1839, OSI-774, PKI 166, EKB-569, GW572016, CEP 2563, UCN-01, GCP 41251 (STI 412), Safingol, Perifosine, SU 5416, CGP 79787, CP-564959, ZD 6474, ZD 2171, SU-11248, Flavopiridol, and CI-202.

11. (Currently Amended) Product[[s]] according to claim 10 wherein the protein kinase inhibitor is selected from the group consisting of STI571, ZD-1839, OSI-774 and SU 5416.

12. (Cancelled)

13. (Currently Amended) Product[[s]] according to claim 9 comprising an acryloyl distamycin derivative of formula (I) wherein R<sub>1</sub> is bromine, R<sub>2</sub> is a group of formula (II) wherein r and m are 0, n is 4, X and Y are CH, B is a group of formula



wherein R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are hydrogen, optionally in the form of a pharmaceutically acceptable salt.

14. (Currently Amended) Product[[s]] according to claim 9 wherein the acryloyl distamycin derivative is selected from the group as defined in claim 7.

15. (Currently Amended) Product[[s]] comprising the acryloyl distamycin derivative N-[5-[[[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[(2-bromo-1-oxo-2-propenyl)amino]-1-methyl-1H-pyrrol-2-yl[carbonyl]amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride (Brostallicin), and a protein kinase inhibitor selected from the group consisting of STI571, ZD-

1839, OSI-774, and SU 5416; as a combined preparation for simultaneous, separate or sequential use in the treatment of tumors.

16.-23. (Cancelled)

24. (Original) A method of treating a mammal, including humans, suffering from a neoplastic disease state, which method comprises administering to said mammal the acryloyl distamycin derivative of formula (I), as defined in claim 1, and a protein kinase inhibitor, in amounts effective to produce a synergistic antineoplastic effect.

25. (Original) A method according to claim 24 wherein the acryloyl distamycin derivative is N-[5-[[[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[(2-bromo-1-oxo-2-propenyl)amino]-1-methyl-1H-pyrrol-2-yl[carbonyl]amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride (Brostallicin), and the protein kinase inhibitor is selected from the group consisting of STI571, ZD-1839, OSI-774, and SU 5416.

26. (Original) A method for lowering the side effects caused by antineoplastic therapy with an antineoplastic agent, in a mammal in need thereof including humans, the method comprising administering to said mammal a combined preparation comprising a protein kinase inhibitor and an acryloyl distamycin derivative of formula (I), as defined in claim 1, in amounts effective to produce a synergistic antineoplastic effect.

27. (Original) A method according to claim 26 wherein the acryloyl distamycin derivative is N-[5-[[[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[(2-bromo-1-oxo-2-propenyl)amino]-1-methyl-1H-pyrrol-2-yl[carbonyl]amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride (Brostallicin), and the protein kinase inhibitor is selected from the group consisting of STI571, ZD-1839, OSI-774, and SU 5416.

28. (New) A method according to claim 24 wherein said disease state is selected from breast, ovary, lung, colon, kidney, stomach, pancreas, liver, melanoma, leukemia and brain tumors.

29. (New) A method of treating metastasis suffered by a mammal, including humans, which method comprises administering to said mammal the acryloyl distamycin derivative of formula (I), as defined in claim 1, and a protein kinase inhibitor, in amounts effective to produce a synergistic antineoplastic effect.

30. (New) A method of treating tumors in a mammal, including humans by inhibition of angiogenesis, which method comprises administering to said mammal the acryloyl distamycin derivative of formula (I), as defined in claim 1, and a protein kinase inhibitor, in amounts effective to produce a synergistic antineoplastic effect.